440 related articles for article (PubMed ID: 27364962)
21. Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson's disease.
Riederer P; Nagatsu T; Youdim MBH; Wulf M; Dijkstra JM; Sian-Huelsmann J
J Neural Transm (Vienna); 2023 May; 130(5):627-646. PubMed ID: 37062012
[TBL] [Abstract][Full Text] [Related]
22. Comparison of α-Synuclein Fibril Inhibition by Four Different Amyloid Inhibitors.
Jha NN; Kumar R; Panigrahi R; Navalkar A; Ghosh D; Sahay S; Mondal M; Kumar A; Maji SK
ACS Chem Neurosci; 2017 Dec; 8(12):2722-2733. PubMed ID: 28872299
[TBL] [Abstract][Full Text] [Related]
23. Models of α-synuclein aggregation in Parkinson's disease.
Giráldez-Pérez R; Antolín-Vallespín M; Muñoz M; Sánchez-Capelo A
Acta Neuropathol Commun; 2014 Dec; 2():176. PubMed ID: 25497491
[TBL] [Abstract][Full Text] [Related]
24. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
25. Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.
Dominguez-Meijide A; Vasili E; König A; Cima-Omori MS; Ibáñez de Opakua A; Leonov A; Ryazanov S; Zweckstetter M; Griesinger C; Outeiro TF
Sci Rep; 2020 Jul; 10(1):12827. PubMed ID: 32732936
[TBL] [Abstract][Full Text] [Related]
26. Comparative Analysis of the Conformation, Aggregation, Interaction, and Fibril Morphologies of Human α-, β-, and γ-Synuclein Proteins.
Jain MK; Singh P; Roy S; Bhat R
Biochemistry; 2018 Jul; 57(26):3830-3848. PubMed ID: 29851342
[TBL] [Abstract][Full Text] [Related]
27. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
Xu S; Chan P
Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
[TBL] [Abstract][Full Text] [Related]
28. Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases.
Gonçalves PB; Sodero ACR; Cordeiro Y
Biomolecules; 2021 May; 11(5):. PubMed ID: 34065606
[TBL] [Abstract][Full Text] [Related]
29. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.
Welander H; Bontha SV; Näsström T; Karlsson M; Nikolajeff F; Danzer K; Kostka M; Kalimo H; Lannfelt L; Ingelsson M; Bergström J
Biochem Biophys Res Commun; 2011 Aug; 412(1):32-8. PubMed ID: 21798243
[TBL] [Abstract][Full Text] [Related]
30. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
31. "Cell-addictive" dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway.
Li Y; Chen Z; Lu Z; Yang Q; Liu L; Jiang Z; Zhang L; Zhang X; Qing H
Theranostics; 2018; 8(19):5469-5481. PubMed ID: 30555558
[TBL] [Abstract][Full Text] [Related]
32. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
[TBL] [Abstract][Full Text] [Related]
33. An Update on the Critical Role of α-Synuclein in Parkinson's Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels.
Serratos IN; Hernández-Pérez E; Campos C; Aschner M; Santamaría A
Mol Neurobiol; 2022 Jan; 59(1):620-642. PubMed ID: 34750787
[TBL] [Abstract][Full Text] [Related]
34. The small aromatic compound SynuClean-D inhibits the aggregation and seeded polymerization of multiple α-synuclein strains.
Peña-Díaz S; Pujols J; Vasili E; Pinheiro F; Santos J; Manglano-Artuñedo Z; Outeiro TF; Ventura S
J Biol Chem; 2022 May; 298(5):101902. PubMed ID: 35390347
[TBL] [Abstract][Full Text] [Related]
35. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
[TBL] [Abstract][Full Text] [Related]
36. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.
Dufty BM; Warner LR; Hou ST; Jiang SX; Gomez-Isla T; Leenhouts KM; Oxford JT; Feany MB; Masliah E; Rohn TT
Am J Pathol; 2007 May; 170(5):1725-38. PubMed ID: 17456777
[TBL] [Abstract][Full Text] [Related]
37. Α-synuclein misfolding and Parkinson's disease.
Breydo L; Wu JW; Uversky VN
Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
[TBL] [Abstract][Full Text] [Related]
38. Amyloid formation and disaggregation of α-synuclein and its tandem repeat (α-TR).
Bae SY; Kim S; Hwang H; Kim HK; Yoon HC; Kim JH; Lee S; Kim TD
Biochem Biophys Res Commun; 2010 Oct; 400(4):531-6. PubMed ID: 20801100
[TBL] [Abstract][Full Text] [Related]
39. α-synuclein aggregation and its modulation.
Ghosh D; Mehra S; Sahay S; Singh PK; Maji SK
Int J Biol Macromol; 2017 Jul; 100():37-54. PubMed ID: 27737778
[TBL] [Abstract][Full Text] [Related]
40. Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies.
Kawahata I; Finkelstein DI; Fukunaga K
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
